RADX FY2026 EPS Decreased by Brookline Capital Markets

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Investment analysts at Brookline Capital Markets dropped their FY2026 earnings per share estimates for Radiopharm Theranostics in a research note issued to investors on Tuesday, July 28th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn ($3.98) per share for the year, down from their previous forecast of ($2.30). The consensus estimate for Radiopharm Theranostics’ current full-year earnings is ($1.80) per share. Brookline Capital Markets also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($3.23) EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright began coverage on shares of Radiopharm Theranostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $11.00.

Radiopharm Theranostics Trading Down 4.8%

Shares of NASDAQ:RADX opened at $3.15 on Thursday. The company’s fifty day moving average is $4.30 and its 200 day moving average is $4.58. Radiopharm Theranostics has a 52 week low of $2.73 and a 52 week high of $16.25.

Institutional Investors Weigh In On Radiopharm Theranostics

Several institutional investors have recently modified their holdings of the business. Marex Group plc bought a new stake in Radiopharm Theranostics in the 4th quarter worth about $54,000. Jane Street Group LLC purchased a new position in Radiopharm Theranostics in the 4th quarter worth about $76,000. Virtu Financial LLC purchased a new position in Radiopharm Theranostics in the 4th quarter worth about $76,000. Finally, Hsbc Holdings PLC bought a new position in Radiopharm Theranostics during the 4th quarter valued at about $1,007,000.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.